$9.35
Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
VIR: Lowering target price to $8.00
VIR: Rating decreased to a SELL
Overview
52-week range
$4.16
$12
69% of range
Avg surprise (last 2)
-8.6%
Avg reaction (last 2)
+1.2%
50% positive
Latest IV / EM
105%
EM ±24.1% · $9 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-0.85 | — | — | +3.4% | +2.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.17 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.80 | $-0.72 | -11.1% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-0.88 | $-0.83 | -6.0% | — | -0.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.56 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.02 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.48 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.22 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.45 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | $0.83 | -$0.80 | +203.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $-29,000 | — | $240,000 | $1M | $3M | — | $2M | $3M |
| Cost of revenue | — | — | — | $11,000 | $0 | — | $50,000 | $52,000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-132M | — | $-173M | $-118M | $-140M | — | $-231M | $-159M |
| Net income | $-126M | — | $-163M | $-111M | $-121M | — | $-214M | $-138M |
| EPS (diluted) | $-0.85 | — | $-1.17 | $-0.80 | $-0.88 | — | $-1.56 | $-1.02 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $274M | $232M | $170M | $211M | $274M | $223M | $168M | $297M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $523M | $514M | $546M | $736M | $932M | $1.04B | $1.05B | $1.21B |
| Total assets | $1.03B | $1.00B | $1.02B | $1.19B | $1.31B | $1.40B | $1.50B | $1.67B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $213M | $238M | $223M | $245M | $264M | $248M | $258M | $236M |
| Total equity | $813M | $765M | $796M | $947M | $1.04B | $1.15B | $1.24B | $1.43B |